Diagnostic Efficacy of Metagenomic Next-generation Sequencing in Patients With Spinal Infections: A Retrospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06172153

Enrollment

100

Registered

2023-12-15

Start date

2023-06-01

Completion date

2024-05-01

Last updated

2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnositic Efficacy, Spinal Infection

Brief summary

Comparing the diagnostic efficacy between traditional laboratory methods and second-generation high-throughput sequencing in patients suspected of spinal infections.

Interventions

OTHERNo interventions

No intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Patients suspected of spinal infections, as per the American Infectious Diseases Society's 2015 criteria for primary vertebral osteomyelitis, were identified based on their clinical symptoms, laboratory tests, and imaging examinations. All cases included in the study underwent laboratory examinations, histopathological examinations, and second-generation high-throughput sequencing (metagenomic sequencing).

Exclusion criteria

The absence of laboratory examinations, histopathological examinations, and results from second-generation high-throughput sequencing (metagenomic sequencing).

Design outcomes

Primary

Measure	Time frame	Description
The diagnositic efficacy	1 year	Sensitivity, Specificity

Countries

China

Contacts

Primary ContactChunhai Li, MD

lichhai@mail.sysu.edu.cn18602079796

Backup Contacthanwen cheng, Master

chenghw3@mail2.sysu.edu.cn19541080926

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026